13 / 17
Page 31
Volume 3
August 5-6, 2019 | Singapore
CANCER RESEARCH AND PHARMACOLOGY
STRUCTURAL BIOCHEMISTRY, STEM CELLS AND MOLECULAR BIOLOGY
24
th
International Conference on
International Congress on
&
Cancer Research 2019 & Structural Biochemistry 2019
August 5-6, 2019
Journal of Cancer and Metastasis Research
Development of aptamer conjugated nanoliposomal flavonoid: A novel therapeutic
approach to treat hepatocellular carcinoma
Moumita Dhara
Jadavpur University, India
H
epatocellular carcinoma (HCC) is one of the major causes of cancer related death globally. Successful treatment of liver
cancer remains a formidable challenge in modern drug development due to sub-therapeutic permeation of conventional
chemotherapeutics to the proper site of action along with its toxic side effects. Ligand conjugated nanoliposomes are an
emerging formulation in the treatment of cancer. Flavonoids are abundantly present in fruits and vegetable are believed to carry
preventive and therapeutic potential against cancer. Here we have optimized the aptamer conjugated nanoliposomes which is
encapsulated with a bio-flavonoid and we studied its preferential uptake and efficacy on liver cancer. Various physiochemical
and biopharmaceutical characterization studies such as drug-excipients interaction, surface morphology, energy dispersive
X-ray analysis, zeta potential,
in vitro
drug release and cytotoxicity along with cellular uptake were conducted. Drug loaded
nanoliposomes (D-NL) and aptamer conjugated drug loaded nanoliposomes (D-NL-A) showed 3.51±0.26% and 3.23±0.05%
drug loading values, respectively. Average diameters (z-average) of the nanoliposomes were within 100 nm; it was also
showed negative zeta potentials along with smooth surface and intact lamellarity. Predominant uptake of both the types of
nanoliposomes was visualized.
In vivo
pharmacokinetic and biodristribution study in swiss albino rats showed that the drug
availability significantly increased in carcinogenic liver upon (D-NL-A) treatment in comparison with free drug and (D-NL).
Ligand conjugated nanoliposomal drug delivery substantially controlled the severity of hepatocellular carcinoma and could be a
future hope for lingering the survival in hepatic cancer patients.
Biography
Moumita Dhara has four years of research expertise in development of novel drug delivery system with its physical and molecular
pharmacological characterization of different nanoformulations upon cancer therapy. Additionally had a previous five years of
pharmaceutical industrial experience in product development and regulatory field. Completed Masters in Pharmacology and presently
pursuing PhD in Pharmacy in Jadavpur University, Kolkata, India.
moumitadhara@yahoo.com